Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant–a case series

Diego Adrianzen Herrera, Sabarish Ayyappan, Sakshi Jasra, Noah Kornblum, Olga Derman, Aditi Shastri, Ioannis Mantzaris, Amit Verma, Ira Braunschweig, Murali Janakiram

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic infection of immunomodulatory therapies. PML cases reported in PubMed (1995–2017) following stem-cell transplantation (HSCT) or chemoimmunotherapy (CIT) for hematologic malignancies were reviewed. We found 107 cases, 40% were HSCT recipients (32 allogeneic, 11 autologous) and 40% indolent lymphomas receiving monoclonal antibodies (mAbs). HSCT cases had longer time to PML diagnosis (10.8 vs. 4 months, p <.001), higher proportion of PML therapy response (58% vs. 25%, p =.019), lower mortality rate (56% vs. 88%, p <.001), and longer median survival (8 vs. 2 months, p <.001). Outcome differences might be caused by selection bias as HSCT patients are most likely treated aggressively; however, time-dependent immune reconstitution might also contribute to their better prognosis. Increased use of mAbs and HSCT are associated with rising PML incidence in hematological malignancies, currently constituting the second largest vulnerable population after HIV-infected patients; further research is needed for its optimal treatment.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalLeukemia and Lymphoma
Volume60
Issue number2
DOIs
StatePublished - Jan 28 2019
Externally publishedYes

Fingerprint

Progressive Multifocal Leukoencephalopathy
Hematologic Neoplasms
Stem Cells
Monoclonal Antibodies
Immunomodulation
Selection Bias
Opportunistic Infections
Stem Cell Transplantation
Vulnerable Populations
PubMed
Lymphoma
HIV
Survival
Mortality
Incidence
Therapeutics
Research

Keywords

  • Progressive multifocal leukoencephalopathy
  • hematologic malignancies
  • monoclonal antibodies
  • stem cell transplantation

PubMed: MeSH publication types

  • Journal Article

Cite this

Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant–a case series. / Adrianzen Herrera, Diego; Ayyappan, Sabarish; Jasra, Sakshi; Kornblum, Noah; Derman, Olga; Shastri, Aditi; Mantzaris, Ioannis; Verma, Amit; Braunschweig, Ira; Janakiram, Murali.

In: Leukemia and Lymphoma, Vol. 60, No. 2, 28.01.2019, p. 395-401.

Research output: Contribution to journalArticle

Adrianzen Herrera, D, Ayyappan, S, Jasra, S, Kornblum, N, Derman, O, Shastri, A, Mantzaris, I, Verma, A, Braunschweig, I & Janakiram, M 2019, 'Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant–a case series', Leukemia and Lymphoma, vol. 60, no. 2, pp. 395-401. https://doi.org/10.1080/10428194.2018.1474523
Adrianzen Herrera, Diego ; Ayyappan, Sabarish ; Jasra, Sakshi ; Kornblum, Noah ; Derman, Olga ; Shastri, Aditi ; Mantzaris, Ioannis ; Verma, Amit ; Braunschweig, Ira ; Janakiram, Murali. / Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant–a case series. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 2. pp. 395-401.
@article{add008a567244fc19345a0439dfa7c3d,
title = "Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant–a case series",
abstract = "Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic infection of immunomodulatory therapies. PML cases reported in PubMed (1995–2017) following stem-cell transplantation (HSCT) or chemoimmunotherapy (CIT) for hematologic malignancies were reviewed. We found 107 cases, 40{\%} were HSCT recipients (32 allogeneic, 11 autologous) and 40{\%} indolent lymphomas receiving monoclonal antibodies (mAbs). HSCT cases had longer time to PML diagnosis (10.8 vs. 4 months, p <.001), higher proportion of PML therapy response (58{\%} vs. 25{\%}, p =.019), lower mortality rate (56{\%} vs. 88{\%}, p <.001), and longer median survival (8 vs. 2 months, p <.001). Outcome differences might be caused by selection bias as HSCT patients are most likely treated aggressively; however, time-dependent immune reconstitution might also contribute to their better prognosis. Increased use of mAbs and HSCT are associated with rising PML incidence in hematological malignancies, currently constituting the second largest vulnerable population after HIV-infected patients; further research is needed for its optimal treatment.",
keywords = "Progressive multifocal leukoencephalopathy, hematologic malignancies, monoclonal antibodies, stem cell transplantation",
author = "{Adrianzen Herrera}, Diego and Sabarish Ayyappan and Sakshi Jasra and Noah Kornblum and Olga Derman and Aditi Shastri and Ioannis Mantzaris and Amit Verma and Ira Braunschweig and Murali Janakiram",
year = "2019",
month = "1",
day = "28",
doi = "10.1080/10428194.2018.1474523",
language = "English (US)",
volume = "60",
pages = "395--401",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant–a case series

AU - Adrianzen Herrera, Diego

AU - Ayyappan, Sabarish

AU - Jasra, Sakshi

AU - Kornblum, Noah

AU - Derman, Olga

AU - Shastri, Aditi

AU - Mantzaris, Ioannis

AU - Verma, Amit

AU - Braunschweig, Ira

AU - Janakiram, Murali

PY - 2019/1/28

Y1 - 2019/1/28

N2 - Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic infection of immunomodulatory therapies. PML cases reported in PubMed (1995–2017) following stem-cell transplantation (HSCT) or chemoimmunotherapy (CIT) for hematologic malignancies were reviewed. We found 107 cases, 40% were HSCT recipients (32 allogeneic, 11 autologous) and 40% indolent lymphomas receiving monoclonal antibodies (mAbs). HSCT cases had longer time to PML diagnosis (10.8 vs. 4 months, p <.001), higher proportion of PML therapy response (58% vs. 25%, p =.019), lower mortality rate (56% vs. 88%, p <.001), and longer median survival (8 vs. 2 months, p <.001). Outcome differences might be caused by selection bias as HSCT patients are most likely treated aggressively; however, time-dependent immune reconstitution might also contribute to their better prognosis. Increased use of mAbs and HSCT are associated with rising PML incidence in hematological malignancies, currently constituting the second largest vulnerable population after HIV-infected patients; further research is needed for its optimal treatment.

AB - Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic infection of immunomodulatory therapies. PML cases reported in PubMed (1995–2017) following stem-cell transplantation (HSCT) or chemoimmunotherapy (CIT) for hematologic malignancies were reviewed. We found 107 cases, 40% were HSCT recipients (32 allogeneic, 11 autologous) and 40% indolent lymphomas receiving monoclonal antibodies (mAbs). HSCT cases had longer time to PML diagnosis (10.8 vs. 4 months, p <.001), higher proportion of PML therapy response (58% vs. 25%, p =.019), lower mortality rate (56% vs. 88%, p <.001), and longer median survival (8 vs. 2 months, p <.001). Outcome differences might be caused by selection bias as HSCT patients are most likely treated aggressively; however, time-dependent immune reconstitution might also contribute to their better prognosis. Increased use of mAbs and HSCT are associated with rising PML incidence in hematological malignancies, currently constituting the second largest vulnerable population after HIV-infected patients; further research is needed for its optimal treatment.

KW - Progressive multifocal leukoencephalopathy

KW - hematologic malignancies

KW - monoclonal antibodies

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85049564267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049564267&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1474523

DO - 10.1080/10428194.2018.1474523

M3 - Article

C2 - 29969336

AN - SCOPUS:85049564267

VL - 60

SP - 395

EP - 401

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -